FDA Fast-Tracks Daraxonrasib for Pancreatic Cancer After 15-Month Survival Data
Updated
Updated · UCHealth Today · Jun 4
FDA Fast-Tracks Daraxonrasib for Pancreatic Cancer After 15-Month Survival Data
3 articles · Updated · UCHealth Today · Jun 4
Summary
May 1 FDA clearance opened expanded access to daraxonrasib for previously treated advanced pancreatic cancer patients, with full approval possible later in 2026.
Trial data presented at ASCO showed patients on once-daily daraxonrasib lived about 15 months, versus historical survival of less than half that, nearly doubling outcomes in a disease that kills about 53,000 Americans yearly.
More than 90% of pancreatic cancers are driven by KRAS mutations, and daraxonrasib works as a pan-RAS inhibitor targeting seven cancer-causing KRAS variants—the first targeted therapy with broad efficacy potential for most patients.
Access is still limited to post-chemotherapy patients whose oncologists must obtain permission from Revolution Medicines, while side effects including rash, diarrhea and nausea were described as generally manageable.
The breakthrough adds momentum to a broader push in pancreatic cancer, including AI tools that flagged 73% of cancers 16 months early in one study and early vaccine research that kept 7 of 8 responders alive at six years.
Could this new drug's success unlock treatments for many other 'undruggable' cancers?
With new drugs, AI, and vaccines emerging, are we finally turning the tide against pancreatic cancer?
Will this breakthrough pancreatic cancer drug be affordable for the average patient?
Daraxonrasib Delivers 13.2-Month Median Survival in Metastatic Pancreatic Cancer: Breakthrough RAS Inhibitor Redefines Treatment Landscape
Overview
In May 2026, the emergence of daraxonrasib marked a major breakthrough for patients with metastatic pancreatic cancer. Rapid developments around this new therapy led to an unprecedented shift in clinical practice and regulatory approaches. Revolution Medicines responded by committing to fast and equitable access for eligible patients in the United States, highlighting the urgency and importance of this treatment. The compelling results from the RASolute 302 trial formed the foundation for accelerated access, showing improved length and quality of life for patients. This progress set the stage for a new era in pancreatic cancer care.